This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Emergent BioSolutions' Management Presents At Wedbush 2012 Life Sciences Management Access Conference Call (Transcript)

Stocks in this article: EBS

Emergent BioSolutions Inc. (EBS)

Wedbush 2012 Life Sciences Management Access Conference Call

August 14, 2012 8:00 am ET


R. Don Elsey – Senior Vice President-Finance & Administration, Chief Financial Officer and Treasurer


Christopher N. Marai – Wedbush Securities, Inc.


Christopher N. Marai – Wedbush Securities, Inc.

Okay, hello good morning. My name is Chris Marai. I’m an analyst here at Wedbush Securities with Greg Wade and David Nierengarten. We’re part of the life science and biotechnology team. And it’s my pleasure to introduce to you today the CFO of Emergent Biosolutions, Don Elsey. He will be telling us a little bit about Emergent’s growing pipeline as well as their BioThrax franchise. Great, thank you Don.

R. Don Elsey

Thank you very much. Good morning to the hearty souls who have made it here so bright and early and I know seats are at premium. So let’s just jump in and get started the typical forward-looking statement where we are going to make some forward-looking statements and actual results may differ from those statements.

So I want to jump in with basically a company overview today. And if you take a look at Emergent just at a glance, we’ve got a proven cash generator in BioThrax, the only anthrax vaccine that’s licensed today. We’ve got two value-creating businesses, were organized into BioDefense and BioSciences. We will get into the structure and the focus of those businesses in a little bit.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs